Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) have rallied 30% over the past five sessions, though are marginally lower Thursday afternoon, as investors anticipate a key catalyst for the company.
What To Know: The biotechnology firm is awaiting a decision from the U.S. Food and Drug Administration (FDA) on its lead drug candidate, TNX-102 SL, for the treatment of fibromyalgia.
